Solid Biosciences (SLDB) Competitors $5.94 +0.28 (+4.95%) (As of 05:13 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends SLDB vs. LOGC, CSBR, PLRX, TYRA, REPL, DNTH, SANA, CRON, ANNX, and ETNBShould you be buying Solid Biosciences stock or one of its competitors? The main competitors of Solid Biosciences include LogicBio Therapeutics (LOGC), Champions Oncology (CSBR), Pliant Therapeutics (PLRX), Tyra Biosciences (TYRA), Replimune Group (REPL), Dianthus Therapeutics (DNTH), Sana Biotechnology (SANA), Cronos Group (CRON), Annexon (ANNX), and 89bio (ETNB). Solid Biosciences vs. LogicBio Therapeutics Champions Oncology Pliant Therapeutics Tyra Biosciences Replimune Group Dianthus Therapeutics Sana Biotechnology Cronos Group Annexon 89bio Solid Biosciences (NASDAQ:SLDB) and LogicBio Therapeutics (NASDAQ:LOGC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, community ranking, institutional ownership and dividends. Does the media prefer SLDB or LOGC? In the previous week, Solid Biosciences had 1 more articles in the media than LogicBio Therapeutics. MarketBeat recorded 1 mentions for Solid Biosciences and 0 mentions for LogicBio Therapeutics. Solid Biosciences' average media sentiment score of 0.59 beat LogicBio Therapeutics' score of 0.00 indicating that Solid Biosciences is being referred to more favorably in the media. Company Overall Sentiment Solid Biosciences Positive LogicBio Therapeutics Neutral Does the MarketBeat Community believe in SLDB or LOGC? Solid Biosciences received 170 more outperform votes than LogicBio Therapeutics when rated by MarketBeat users. Likewise, 68.15% of users gave Solid Biosciences an outperform vote while only 64.08% of users gave LogicBio Therapeutics an outperform vote. CompanyUnderperformOutperformSolid BiosciencesOutperform Votes26168.15% Underperform Votes12231.85% LogicBio TherapeuticsOutperform Votes9164.08% Underperform Votes5135.92% Do analysts recommend SLDB or LOGC? Solid Biosciences presently has a consensus price target of $15.67, indicating a potential upside of 172.94%. Given Solid Biosciences' higher probable upside, equities research analysts clearly believe Solid Biosciences is more favorable than LogicBio Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Solid Biosciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25LogicBio Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Do insiders and institutionals hold more shares of SLDB or LOGC? 81.5% of Solid Biosciences shares are owned by institutional investors. Comparatively, 46.1% of LogicBio Therapeutics shares are owned by institutional investors. 13.6% of Solid Biosciences shares are owned by company insiders. Comparatively, 0.4% of LogicBio Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more volatility & risk, SLDB or LOGC? Solid Biosciences has a beta of 1.92, meaning that its stock price is 92% more volatile than the S&P 500. Comparatively, LogicBio Therapeutics has a beta of 2.05, meaning that its stock price is 105% more volatile than the S&P 500. Is SLDB or LOGC more profitable? Solid Biosciences has a net margin of 0.00% compared to LogicBio Therapeutics' net margin of -141.03%. Solid Biosciences' return on equity of -53.76% beat LogicBio Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Solid BiosciencesN/A -53.76% -43.74% LogicBio Therapeutics -141.03%-109.05%-62.15% Which has better valuation & earnings, SLDB or LOGC? Solid Biosciences has higher earnings, but lower revenue than LogicBio Therapeutics. Solid Biosciences is trading at a lower price-to-earnings ratio than LogicBio Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSolid Biosciences$8.09M27.67-$96.01M-$3.30-1.76LogicBio Therapeutics$287M0.58-$317M-$9.10-0.70 SummarySolid Biosciences beats LogicBio Therapeutics on 15 of the 18 factors compared between the two stocks. Ad Crypto 101 MediaBlackrock’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get Solid Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SLDB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLDB vs. The Competition Export to ExcelMetricSolid BiosciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$223.88M$3.14B$5.19B$8.55BDividend YieldN/A1.76%5.06%4.17%P/E Ratio-1.767.62106.1014.37Price / Sales27.67325.241,643.8695.76Price / CashN/A147.3233.9831.46Price / Book0.934.024.754.62Net Income-$96.01M-$42.25M$116.42M$223.41M7 Day Performance1.93%0.13%-0.78%-0.31%1 Month Performance-11.85%8.39%5.58%3.98%1 Year Performance104.23%28.33%33.83%26.39% Solid Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLDBSolid Biosciences3.0198 of 5 stars$5.94+4.9%$15.67+163.7%+99.3%$229.25M$8.09M-1.80100Positive NewsLOGCLogicBio Therapeutics0.449 of 5 stars$6.49-1.2%N/AN/A$172.62M$287M-0.7162CSBRChampions Oncology4.269 of 5 stars$3.91+3.2%$6.00+53.5%-27.4%$51.52M$50.15M-15.04143Positive NewsHigh Trading VolumePLRXPliant Therapeutics4.1023 of 5 stars$14.07-2.4%$40.57+188.4%-10.1%$876.15M$1.58M-4.5590TYRATyra Biosciences3.77 of 5 stars$16.68+4.4%$31.40+88.2%+20.9%$843.31MN/A-9.8720Gap UpREPLReplimune Group3.6904 of 5 stars$11.76-2.9%$16.80+42.9%-15.4%$827.37MN/A-3.60210DNTHDianthus Therapeutics1.4157 of 5 stars$27.86-0.4%$45.14+62.0%+135.7%$821.08M$2.83M-5.0380News CoverageSANASana Biotechnology2.1364 of 5 stars$3.50-4.4%$14.25+307.1%+6.5%$814.22MN/A-3.04328Analyst ForecastNews CoverageGap DownCRONCronos Group1.2971 of 5 stars$2.09-0.9%$3.00+43.5%+18.3%$806.64M$87.24M-13.93356Upcoming EarningsNews CoverageANNXAnnexon1.4105 of 5 stars$7.32-2.9%$15.80+115.8%+173.7%$796.63MN/A-5.9560Upcoming EarningsETNB89bio1.8741 of 5 stars$7.78-2.6%$31.00+298.5%+10.5%$786.09MN/A-3.9540Gap Down Related Companies and Tools Related Companies LogicBio Therapeutics Competitors Champions Oncology Competitors Pliant Therapeutics Competitors Tyra Biosciences Competitors Replimune Group Competitors Dianthus Therapeutics Competitors Sana Biotechnology Competitors Cronos Group Competitors Annexon Competitors 89bio Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SLDB) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredMissed Out On Nvidia?Artificial Intelligence is a tool with the potential to create massive distributions of wealth… In fact, it...Unstoppable Prosperity | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredHow high could Bitcoin go?Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally c...Porter & Company | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Solid Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Solid Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.